Background and objectives The estimation of a cost-Effectiveness (CE) threshold from the
perspective of those who have experienced a life-threatening disease can provide empirical …

Background Empirical support for the appropriate cost-effectiveness threshold (CET) in
China remains sparse. Objective This study aimed to estimate the willingness to pay (WTP) …

Aim: To provide an overview of thresholds for incremental cost–effectiveness ratios (ICERs)
representing willingness-to-pay (WTP) across multiple countries and insights into …

Background Cost-effectiveness analyses rarely offer useful insights to policy decisions
unless their results are compared against a benchmark threshold. The cost-effectiveness …

Background Debate on pricing and reimbursement of cancer medicines highlights the need
to establish the value of cancer medicines. Objective This study aims to elicit the trade-offs in …

Objectives This study aimed to systematically review the use of cost-effectiveness (CE)
threshold for evaluating pharmacological interventions in Greece. Methods A systematic …

Background In line with global trends, cancer incidence and mortality may have decreased
for specific types of cancer in Qatar. However, the cancer-related burden on patients …

Background Cost-effectiveness analysis provides a crucial means for evidence-informed
decision-making on resource allocation. This study aims to elicit individuals' willingness to …

Background Understanding patient preferences in cancer management is essential for
shared decision-making. Patient or societal willingness-to-pay (WTP) for desired outcomes …

For the assessment of value of new therapies in healthcare, Health Technology Assessment
(HTA) agencies often review the cost per quality-adjusted life-year (QALY) gained. Some …